Abstract
Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Current Psychopharmacology
Title: Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Volume: 1
Author(s): Giampaolo Tomasi
Affiliation:
Keywords: Binding potential (BP), competition model, endogenous neurotransmitter (EN), internalization model, pharmacological challenge, positron emission tomography (PET), serotonin, opioid peptides, acetylcholine, Parkinson's disease, amphetamine, epidepride, methylspiperone, fallypride, Antagonist Tracers
Abstract: Positron Emission Tomography (PET) can be used to assess changes of endogenous neurotransmitters induced by pharmacological or physiological challenges and has been successfully applied to the study of the dopaminergic system, and, to a lower extent, to the serotonergic, opioid and cholinergic systems. This review first introduces the principles underlying the assessment of fluctuations of endogenous neurotransmitters with PET and then summarizes the main results obtained for dopamine, with emphasis on clinical studies. The studies of serotonin, opioid peptides, acetylcholine and the few studies dealing with other neurotransmitters (GABA, glutamate) are subsequently reviewed. In conclusion the chances of successfully imaging endogenous neurotransmitters with PET as well as possible trends for the future are discussed.
Export Options
About this article
Cite this article as:
Tomasi Giampaolo, Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010029
DOI https://dx.doi.org/10.2174/2211556011201010029 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Gene Delivery for Cancer Therapy
Current Drug Delivery Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Histone Acetyltransferases in Plant Development and Plasticity
Current Genomics Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Mouse Strains for Prostate Tumorigenesis Based on Genes Altered in Human Prostate Cancer
Current Drug Targets Gene Therapy for Ocular Neovascularization
Current Gene Therapy The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology The Different Roles of The Channel-Kinases TRPM6 and TRPM7
Current Medicinal Chemistry